2025 was rich in successful stories. Here are the top 10 that impressed our audience.
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.

